The Food and Drug Administration (FDA)-approved molecule memantine targets glutamate receptors and is among the few pharmacological treatments that provide modest benefits in AD patients, in addition to cholinesterase inhibitors [145]. Here, BCHE is linked to Alzheimer disease.